Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations

EASL-EORTC clinical practice guidelines (2012) management of hepatocellular carcinoma. J Hepatol 56(4):908–943

Article  Google Scholar 

Sayiner M, Golabi P, Younossi ZM (2019) Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci 64(4):910–917

Article  CAS  PubMed  Google Scholar 

Singal AG, El-Serag HB (2015) Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 13(12):2140–2151

Article  PubMed  PubMed Central  Google Scholar 

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589–604

Article  PubMed  PubMed Central  Google Scholar 

Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F (2020) Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 7(3):Hep27

Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M (2008) Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol 22(6):1137–1151

Article  PubMed  Google Scholar 

Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J (2019) Controversies in the management of hepatocellular carcinoma. JHEP Rep 1(1):17–29

Article  PubMed  PubMed Central  Google Scholar 

Zhou K, Fountzilas C (2019) Outcomes and quality of life of systemic therapy in advanced hepatocellular carcinoma. Cancers (Basel) 11(6)

Pinter M, Scheiner B, Peck-Radosavljevic M (2021) Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 70(1):204–214

Article  CAS  PubMed  Google Scholar 

Popescu I (2010) Hepatocellular carcinoma–new trends. Memo-Mag Eur Med  3:113–118

Sirohi B, Shrikhande SV, Gaikwad V, Patel A, Patkar S, Goel M, Bal M, Sharma A, Shrimali RK, Bhatia V et al (2020) Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res 152(5):468–474

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y (2020) Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res 10(9):2993–3036

CAS  PubMed  PubMed Central  Google Scholar 

Booth JP, Pilz J (2022) Retrospective indication-matched cohort study of reference product and biosimilar: bevacizumab versus bevacizumab-Awwb. Hosp Pharm 57(4):455–461

Article  CAS  PubMed  Google Scholar 

Dekervel J, van Pelt J, Verslype C (2013) Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding? Curr Opin Oncol 25(4):409–416

Article  CAS  PubMed  Google Scholar 

Hato T, Zhu AX, Duda DG (2016) Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 8(3):299–313

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koilakou S, Petrou P (2021) Economic evaluation of monoclonal antibodies in metastatic colorectal cancer: a systematic review. Mol Diagn Ther 25(6):715–734

Article  CAS  PubMed  Google Scholar 

Su D, Wu B, Shi L (2021) Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open 4(2):e210037

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Yuen SC, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, Mattingly TJ 2nd (2022) A systematic review of cost-effectiveness analyses for hepatocellular carcinoma treatment. Pharmacoecon Open 6(1):9–19

Article  PubMed  Google Scholar 

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E et al (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health 25(1):3–9

Article  PubMed  Google Scholar 

Guan H, Wang C, Zhao Z, Han S (2022) Cost-effectiveness of donafenib as first-line treatment of unresectable hepatocellular carcinoma in China. Adv Ther 39(7):3334–3346

Article  PubMed  Google Scholar 

Cai H, Zhang L, Li N, Zheng B, Liu M (2020) Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. J Comp Eff Res 9(8):553–562

Article  PubMed  Google Scholar 

Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S (2019) Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol 54(6):558–570

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ikeda S, Kudo M, Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S (2021) Cost-effectiveness of lenvatinib in the treatment of patients with unresectable hepatocellular carcinomas in Japan: an analysis using data from Japanese patients in the REFLECT trial. Value Health Reg Issues 24:82–89

Article  PubMed  Google Scholar 

Meng R, Zhang X, Zhou T, Luo M, Qiu Y (2022) Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res 22(7):1079–1086

Article  PubMed  Google Scholar 

Zhao M, Pan X, Yin Y, Hu H, Wei J, Bai Z, Tang W (2022) Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis. Front Public Health 10:869960

Article  PubMed  PubMed Central  Google Scholar 

Sherrow C, Attwood K, Zhou K, Mukherjee S, Iyer R, Fountzilas C (2020) Sequencing systemic therapy pathways for advanced hepatocellular carcinoma: a cost effectiveness analysis. Liver Cancer 9(5):549–562

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyers BM, Vogel A, Marotta P, Kavan P, Kamboj L, Pan J, Geadah M, Trueman D, Sabapathy S (2021) The cost-effectiveness of lenvatinib in the treatment of advanced or unresectable hepatocellular carcinoma from a Canadian perspective. Can J Gastroenterol Hepatol 2021:8811018

Article  PubMed  PubMed Central  Google Scholar 

Kim JJ, McFarlane T, Tully S, Wong WWL (2020) Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost-utility analysis. Oncologist 25(3):e512–e519

Article  CAS  PubMed  Google Scholar 

Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M (2020) Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clin Drug Investig 40(12):1167–1176

Article  PubMed  Google Scholar 

Johannsen L, Brandt M, Frerichs W, Inhestern L, Bergelt C (2022) The impact of cancer on the mental health of patients parenting minor children: a systematic review of quantitative evidence. Psychooncology 31(6):869–878

Article  PubMed  Google Scholar 

Oechsle K, Ullrich A, Marx G, Benze G, Wowretzko F, Zhang Y, Dickel LM, Heine J, Wendt KN, Nauck F et al (2020) Prevalence and predictors of distress, anxiety, depression, and quality of life in bereaved family caregivers of patients with advanced cancer. Am J Hosp Palliat Care 37(3):201–213

Article  PubMed  Google Scholar 

Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316(10):1093–1103

Article  PubMed  Google Scholar 

Drummond M, Brandt A, Luce B, Rovira J (1993) Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care 9(1):26–36

留言 (0)

沒有登入
gif